paroxysmal nocturnal hemoglobinuria (PNH) | Page 31 | Aplastic Anemia & MDS International Foundation

paroxysmal nocturnal hemoglobinuria (PNH)

Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

Author(s): 
Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P.
Primary Author: 
Kelly RJ
Journal Title: 
Blood
Original Publication Date: 
Apr 2011

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder with increased mortality and morbidity due to intense intravascular

Loss of expression of neutrophil proteinase-3: a contributory factor in thrombotic risk in paroxysmal nocturnal hemoglobinuria.

Author(s): 
Jankowska AM, Szpurka H, Calabro M, Mohan S, Schade AE, Clemente M, Silverstein RL, Maciejewski JP
Primary Author: 
Jankowska AM
Journal Title: 
Haematologica
Original Publication Date: 
May 2011

Background: A deficiency of specific glycosylphosphatidyl inositol-anchored proteins in paroxysmal nocturnal hemoglobinuria may be responsible for most of the clinical features of this disease, but some functional consequences may be indirect. For example, the absence of certain glycosylphosphatidyl

Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.

Author(s): 
Scheinberg P, Marte M, Nunez O, Young NS.
Primary Author: 
Scheinberg P
Journal Title: 
Haematologica
Original Publication Date: 
Jul 2010

BACKGROUND:

Clones of glycosylphosphatidylinositol-anchor protein-deficient cells are

Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia.

Author(s): 
Pu JJ, Mukhina G, Wang H, Savage WJ, Brodsky RA.
Primary Author: 
Pu JJ
Journal Title: 
Eur J Haematol
Original Publication Date: 
Mar 2011

Objective:  Investigate the natural history of PNH

Patients

AAMDSIF hosts Patient & Family Conferences around the United States each year. Conferences are free to attend and include presentations by the leading medical experts in rare blood cancers and bone marrow failure diseases. It is also an incredible and important opportunity for patients to connect with one another and share support, answers and hope.

2020 dates and locations announced. Registration is now open! LEARN MORE